Peptic Ulcers Treatment Market Size & Growth Forecast 2027–2036, By Segments (Ulcer Type, Distribution Channel, Drug Type, Medication Type, Route of Administration), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Peptic Ulcers Treatment Market size was around USD 5.57 billion in 2026 and is slated to grow at a 5.62% CAGR from 2027 to 2036, crossing USD 9.62 billion by 2036. The industry revenue for 2027 is assessed at USD 5.84 billion.
Get more details on this report
Request Free Sample ReportPeptic Ulcers Treatment Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 43.67% market share in 2026, supported by advanced healthcare infrastructure, accessible diagnostics, established treatment practices, and strong healthcare expenditure supporting timely diagnosis and treatment.
- Asia Pacific is the fastest-growing region, driven by its large patient population, improving healthcare access, greater awareness of gastrointestinal disorders, and wider availability of diagnostic services and modern therapies.
Segment Momentum
- Duodenal ulcers accounted for 52.32% of the market in 2026, supported by demand for therapies that reduce acid exposure, promote ulcer healing, and help prevent recurrence.
- Proton pump inhibitors held a 47.81% market share in 2026 and are also the fastest-growing drug segment, driven by their established role in acid suppression and ulcer healing.
Market Expansion Drivers
- Increased H. pylori screening & diagnosis initiatives.
- Adoption of novel drug therapies & combination regimens.
- Growing awareness & preventive care programs.
Leading Market Participants
- Prominent players in the peptic ulcers treatment market include AstraZeneca (United Kingdom), Takeda Pharmaceutical (Japan), Pfizer (United States), GlaxoSmithKline (United Kingdom), AbbVie (United States), Sanofi (France), Bayer (Germany), Johnson & Johnson (United States), Sun Pharmaceutical (India), Dr. Reddy’s Laboratories (India).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 5.57 billion
- 2027 Estimated Market Size: USD 5.84 billion
- Projected Market Size: USD 9.62 billion by 2036
- Growth Forecast: 5.62% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Ulcer Type (Duodenal Ulcers) | Distribution Channel (Retail Pharmacies) | Drug Type (Proton Pump Inhibitors (PPIs)) | Medication Type (Generics) | Route of Administration (Oral)
- Emerging Opportunity Segment: Ulcer Type (Duodenal Ulcers) | Distribution Channel (Retail Pharmacies) | Drug Type (Proton Pump Inhibitors (PPIs)) | Medication Type (Generics) | Route of Administration (Oral)
Market Growth Drivers and Industry Trends
Increased H. pylori screening & diagnosis initiatives
The expansion of screening and diagnostic initiatives for H. pylori infection is supporting the growth of the peptic ulcers treatment market by enabling earlier identification of a major underlying cause of ulcer development. Greater emphasis on gastrointestinal health, improved diagnostic awareness, and routine evaluation of persistent digestive symptoms are encouraging more patients to undergo testing. Earlier detection allows healthcare providers to initiate appropriate treatment and reduce the risk of recurrent ulcers and related complications.
Adoption of novel drug therapies & combination regimens
The adoption of newer drug therapies and combination treatment regimens is contributing to market growth by expanding therapeutic approaches for managing peptic ulcers and associated infections. Healthcare providers are increasingly seeking treatment strategies that address underlying causes, improve symptom control, and reduce recurrence. Continued advancements in therapeutic formulations and treatment protocols are supporting more targeted management while encouraging greater use of comprehensive regimens in clinical practice.
Growing awareness & preventive care programs
Growing awareness of peptic ulcer symptoms, risk factors, and potential complications is encouraging individuals to seek medical attention earlier and participate in preventive healthcare initiatives. Public health education, gastrointestinal wellness programs, and greater access to medical information are improving recognition of persistent digestive symptoms and the importance of timely evaluation. This increased focus on prevention and early intervention is supporting diagnosis and treatment demand while helping reduce the likelihood of severe ulcer-related complications.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increased H. pylori screening & diagnosis initiatives | 1.6% | Short term (≤ 2 yrs) | North America; Europe | Medium | Fast |
| Adoption of novel drug therapies & combination regimens | 1.4% | Medium term (2–5 yrs) | North America; Asia Pacific | High | Moderate |
| Growing awareness & preventive care programs | 1.2% | Long term (5+ yrs) | Europe; Latin America spillover | Low | Slow |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America accounted for 43.67% share of the peptic ulcers treatment market in 2026, impelled by advanced healthcare infrastructure, widespread access to diagnostic services, and established treatment practices for gastrointestinal disorders. The regional market benefits from growing awareness of peptic ulcer disease and its associated complications, encouraging patients to seek timely diagnosis and treatment. Continued use of pharmacological therapies for acid reduction and infection management is supporting demand for ulcer treatments, while improvements in diagnostic capabilities are enabling earlier identification of gastrointestinal conditions. Strong healthcare expenditure and access to specialized medical care further contribute to the region's established market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region in the peptic ulcers treatment market, spurred by a large patient population, improving healthcare access, and increasing awareness of gastrointestinal disorders. Expansion of healthcare infrastructure and greater availability of diagnostic and treatment services are supporting earlier identification and management of peptic ulcers. Growing urban populations, changing dietary patterns, and increasing attention to digestive health are also contributing to demand for effective treatment options. Improvements in healthcare delivery and rising access to modern therapies are further supporting market development across both emerging and developed economies in the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Advanced Ulcer ManagementThe U.S. market emphasizes evidence-based ulcer diagnosis, acid-suppression therapies, and management of H. pylori infection. Provider efforts increasingly center on appropriate treatment selection, medication adherence, and reducing recurrence through structured follow-up.
Germany 🇩🇪
Guideline-Based CareGermany places strong emphasis on standardized gastrointestinal care, diagnostic evaluation, and appropriate pharmacological treatment. Clinical priorities include accurate H. pylori detection, rational proton pump inhibitor use, and monitoring patients with recurrent or medication-associated ulcers.
Japan 🇯🇵
Integrated GI TreatmentJapan's peptic ulcer treatment landscape combines established pharmacological therapies with detailed gastrointestinal diagnostics. Treatment priorities include H. pylori eradication, endoscopic assessment, and careful management of recurrence, particularly among patients requiring long-term medication.
South Korea 🇰🇷
Eradication-Focused TherapySouth Korea's market is closely tied to H. pylori management and gastrointestinal diagnostic practices. Providers prioritize eradication therapy, confirmation of treatment success, and appropriate acid suppression, while endoscopic evaluation remains important for distinguishing ulcers from serious gastric conditions.
France 🇫🇷
Coordinated Ulcer CareFrance emphasizes clinically appropriate diagnosis and pharmacological management of peptic ulcers, supported by established gastroenterology services. Key priorities include H. pylori eradication, responsible acid-suppressing therapy, and follow-up for patients at risk of recurrent disease.
Italy 🇮🇹
Gastroenterology-Centered TreatmentItaly's treatment environment focuses on combining diagnostic evaluation with established drug therapies for ulcer disease. H. pylori testing and eradication, endoscopic assessment, and management of recurrence remain practical priorities across gastroenterology and primary-care pathways.
Peptic Ulcers Treatment Market Share (%), by Ulcer Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportUlcer Type Segment Analysis: Duodenal Ulcers (Largest & Fastest-Growing Segment)
The duodenal ulcers segment accounted for the largest 2026 market share of 52.32% in the peptic ulcers treatment market, driven by the continued demand for effective therapeutic approaches addressing inflammation, mucosal damage, and acid-related complications associated with duodenal ulcer conditions. Treatment management typically emphasizes reducing gastric acid exposure, supporting ulcer healing, and preventing recurrence, which sustains demand for established pharmacological therapies. The segment is also expected to register the fastest growth, supported by continued diagnosis and treatment of duodenal ulcer cases, greater awareness of gastrointestinal disorders, and increasing emphasis on timely intervention to minimize complications. Improvements in diagnostic practices and the broader availability of ulcer-management therapies are further supporting treatment adoption in this segment.
Distribution Channel Segment Analysis: Retail Pharmacies (Largest & Fastest-Growing Segment)
The retail pharmacies segment accounted for the largest market share of 46.64% in 2026, supported by the accessibility and convenience of community-based pharmacies for patients seeking medications for gastrointestinal conditions. Retail pharmacies provide a readily available channel for obtaining prescribed and commonly used ulcer treatments while enabling patients to access medications close to their homes and healthcare providers. The segment is also expected to register the fastest growth, driven by expanding pharmacy networks, increasing demand for convenient medication access, and continued reliance on outpatient treatment for peptic ulcer conditions. Greater patient awareness, recurring treatment requirements, and improvements in pharmacy-based medication availability are further strengthening the role of retail pharmacies in the distribution of peptic ulcer therapies.
Drug Type Segment Analysis: Proton Pump Inhibitors (PPIs) (Largest & Fastest-Growing Segment)
The proton pump inhibitors (PPIs) segment accounted for the largest share of 47.81% in the peptic ulcers treatment market in 2026, primarily due to the established role of PPIs in suppressing gastric acid production and supporting the healing of acid-related gastrointestinal lesions. Their use in managing peptic ulcer disease, particularly where reduction of gastric acidity is central to treatment, contributes to strong demand across clinical and outpatient settings. The segment is also expected to register the fastest growth, supported by continued preference for effective acid-suppression therapies and the growing focus on rapid symptom management and ulcer healing. Increasing diagnosis of gastrointestinal disorders, ongoing treatment of acid-related conditions, and broader access to PPI-based therapies are contributing to sustained adoption in the drug type segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Ulcer Type | Gastric Ulcers, Duodenal Ulcers, Esophageal Ulcers | Duodenal Ulcers | Duodenal Ulcers |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies | Retail Pharmacies | Retail Pharmacies |
| Drug Type | Proton Pump Inhibitors (PPIs), H2-receptor Antagonists, Antacids, Antibiotics, Cytoprotective Agents, Others | Proton Pump Inhibitors (PPIs) | Proton Pump Inhibitors (PPIs) |
| Medication Type | Branded, Generics | Generics | Generics |
| Route of Administration | Oral, Parenteral | Oral | Oral |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
The competitive landscape for peptic ulcer treatments extends beyond acid suppression to encompass successful eradication of underlying infections, treatment tolerability, and patient adherence. Proton pump inhibitors remain important for reducing gastric acidity and supporting ulcer healing, but outcomes depend on the cause of the ulcer and the wider treatment regimen. For Helicobacter pylori-associated ulcers, antimicrobial resistance makes regimen selection increasingly consequential, while confirmed eradication provides a more meaningful measure of treatment success than prescribing activity alone. Mucosal protective agents can complement treatment strategies but do not replace therapies targeting the underlying cause. Combination regimens also face practical barriers, including dosing complexity, adverse effects, and premature discontinuation. Accordingly, differentiation rests on clinical effectiveness, tolerability, appropriate regimen selection, and the feasibility of completing treatment successfully.
Key companies in the peptic ulcers treatment market:
- AstraZeneca (United Kingdom)
- Takeda Pharmaceutical (Japan)
- Pfizer (United States)
- GlaxoSmithKline (United Kingdom)
- AbbVie (United States)
- Sanofi (France)
- Bayer (Germany)
- Johnson & Johnson (United States)
- Sun Pharmaceutical (India)
- Dr. Reddy’s Laboratories (India)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| AstraZeneca (United Kingdom) | |||||||
| Takeda Pharmaceutical (Japan) | |||||||
| Pfizer (United States) | |||||||
| GlaxoSmithKline (United Kingdom) | |||||||
| AbbVie (United States) | |||||||
| Sanofi (France) | |||||||
| Bayer (Germany) | |||||||
| Johnson & Johnson (United States) | |||||||
| Sun Pharmaceutical (India) | |||||||
| Dr. Reddy’s Laboratories (India) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Zydus Lifesciences | February 2025 | Zydus Lifesciences received final approval from the U.S. FDA to manufacture and market Ibuprofen and Famotidine tablets, formulated to treat arthritis conditions while simultaneously reducing the risk of upper gastrointestinal ulcers. This regulatory clearance broadens the company's gastrointestinal portfolio and addresses increasing clinical demand for ulcer-protective therapies. |
| Dr. Reddy's Laboratories | July 2024 | Dr. Reddy's Laboratories secured a non-exclusive patent licensing agreement with Takeda Pharmaceutical to commercialize Vonoprazan tablets under the brand name VONO in 10mg and 20mg strengths within the Indian market. As an advanced oral acid blocker used for acid-peptic disorders, this agreement expands the company's specialized treatment portfolio. |
| Strides Pharma | May 2024 | Strides Pharma received U.S. FDA approval for its generic Sucralfate Oral Suspension, 1gm/10mL, establishing therapeutic equivalence to the reference listed drug Carafate. This regulatory milestone strengthens the company's market footprint in gastrointestinal therapeutics and broadens commercial access to affordable peptic ulcer treatments in the U.S. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Peptic Ulcers Treatment Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Treatment Line | First-line therapy, Second-line therapy, Third-line and salvage therapy |
| Etiological Factor | Helicobacter pylori-associated ulcers, NSAID-associated ulcers, Stress-related and other ulcers |
| Prescribing Setting | Hospitals and specialty clinics, Primary care clinics, Ambulatory care centers, Telemedicine and virtual care |
Peptic Ulcers Treatment Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Treatment Pathway Evolution |
|
| Patient Adherence & Persistence |
|
| Unmet Needs in Refractory Ulcers |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the overall size of the peptic ulcers treatment market?
What are the growth projections for the peptic ulcers treatment industry?
How are expanded H. pylori screening initiatives influencing treatment demand for peptic ulcers?
How are newer therapies and preventive care programs shaping treatment adoption in the peptic ulcers market?
Why do duodenal ulcers lead demand in the peptic ulcers treatment market?
Why are proton pump inhibitors preferred in peptic ulcer treatment?
Why does North America hold the largest share of the peptic ulcers treatment market?
What is driving the fastest growth in the Asia Pacific peptic ulcers treatment market?
Which organizations are considered leaders in the peptic ulcers treatment landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook